English Summary
Licai Gansu Xifeng Pharmaceutical Co., Ltd. is a China Little Giant company report summary for overseas readers. The company is associated with Gansu. The report is indexed under Biomedicine. The Chinese report was published on 2026-06-14. The summary covers company profile, product direction, industry-chain role, technology, patent/R&D signals, scale indicators and policy-material checkpoints.
Report Snapshot
| Company | Licai Gansu Xifeng Pharmaceutical Co., Ltd. |
| Region | Gansu |
| Industry | Biomedicine |
| Published | 2026-06-14 |
| Chinese report | Open |
Company and Recognition Snapshot
Licai Gansu Xifeng Pharmaceutical Co., Ltd. is indexed as a national-level Little Giant enterprise in Gansu. The English profile places the company under Biomedicine and records 2020 2nd batch as the available recognition context.
| Recognition batch | 2020 2nd batch |
| Region | Gansu |
| Industry | Biomedicine |
| Registered capital | RMB 35.10 million |
| Employee signal | 278 employees |
| Listed status | Not listed |
| Patent signal | Patent count not available |
| R&D signal | R&D investment detail not published in the English dataset |
Business and Industry-chain Position
Chinese public records indicate medical-device or biomedicine activity, R&D, design and engineering activity. The recorded industry-chain position is Biomedicine and medical devices / Recorded position. This places the company in a policy-relevant segment for peer comparison by region, industry and batch.
Technology, Patent and R&D Signals
The public profile records Patent count not available. The R&D signal is: R&D investment detail not published in the English dataset. Patent and R&D information should be read with product direction, customer evidence and chain position rather than as isolated threshold items.
Policy-material Review Points
- Verify whether the company's main business, niche market and product evidence all point to Biomedicine.
- Check that patent, R&D, employee and financial fields support the same core product direction.
- Compare the company with peers in the same province, industry and recognition batch before using the profile for supplier screening or policy research.
- Use the linked Chinese source report for original-language evidence and source links.
Original Report and Profile
For the underlying database record, open the English company profile. For full-length analysis, original-language wording and public evidence links, open the Chinese source report.